New Roche Breast Cancer Treatment Approved In US


Date:

(MENAFN- Swissinfo) Swiss pharmaceutical giant Roche is set to launch a new oral treatment for hormone-dependent breast cancer on the US market. It could generate up to CHF500 million ($592 million) as early as next year. This content was published on November 17, 2026 - 13:50 4 minutes Keystone-SDA
    Français fr Roche: un nouveau traitement du cancer du sein homologué aux USA Original Read more: Roche: un nouveau traitement du cancer du sein homologué au

+Get the most important news from Switzerland in your inbox

The US drug regulator, the Food and Drug Administration (FDA), has approved Wilserdly (giredestrant) in combination with everolimus for use in patients with oestrogen receptor (ER)-positive breast cancer, with HER2-negative status (human epidermal growth factor receptor 2) and an ESR1 gene mutation, in locally advanced or metastatic disease, according to a press release.

When contacted by the AWP news agency, the group said it expects the launch to contribute to the company's sales from next year onwards,“with 2027 representing Wilserdly's first full year on the market”.

The consensus estimate puts revenue in the range of $500-600 million,“which is in line with our expectations”. By way of comparison, Roche recorded revenue of CHF61.52 billion in 2025, of which CHF48 billion came from its pharmaceuticals division.

Analyst Urban Fritsche of Zurich Cantonal Bank (ZKB) estimates that the treatment could generate up to CHF14 billion in sales at its peak in 2033, while the consensus forecast stands at CHF4.2 billion.

Roche told AWP that the therapy is being marketed“at a list price of $22,500 per month”, while emphasising that this amount will not necessarily correspond to what patients will actually pay, depending on coverage by their insurance or public assistance schemes.

This price is on a par with the Inluriyo (imlunestrant) treatment from US competitor Eli Lilly, but is cheaper than Etcamah (camizestrant) from UK-based AstraZeneca, notes the Royal Bank of Canada (RBC) in a commentary.

More More Drug pricing How a clash with Roche exposed cracks in Swiss drug pricing system

This content was published on Sep 19, 2025 Switzerland's new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.

Read more: How a clash with Roche exposed cracks in Swiss drug pricing s

MENAFN17112026000210011054ID1111978294


Swissinfo

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search